OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial
Prashant Kapoor, Shaji Kumar(Mayo Clinic), Natalie S. Callander(University of Wisconsin–Madison), Susanna Jacobus(Harvard University), S. Vincent Rajkumar(WinnMed), Timothy M. Schmidt(University of Wisconsin–Madison), Rafaël Fonseca(Mayo Clinic in Arizona), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), Sagar Lonial(Emory University)
Cited by 16
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k